CL2008000804A1 - Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible. - Google Patents

Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible.

Info

Publication number
CL2008000804A1
CL2008000804A1 CL200800804A CL2008000804A CL2008000804A1 CL 2008000804 A1 CL2008000804 A1 CL 2008000804A1 CL 200800804 A CL200800804 A CL 200800804A CL 2008000804 A CL2008000804 A CL 2008000804A CL 2008000804 A1 CL2008000804 A1 CL 2008000804A1
Authority
CL
Chile
Prior art keywords
copper salt
digerable
masked
treatment
pharmaceutical composition
Prior art date
Application number
CL200800804A
Other languages
English (en)
Spanish (es)
Inventor
Jacques Y Kis Geo Vandermander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000804(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008000804A1 publication Critical patent/CL2008000804A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CL200800804A 2007-03-23 2008-03-20 Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible. CL2008000804A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07111322 2007-06-28

Publications (1)

Publication Number Publication Date
CL2008000804A1 true CL2008000804A1 (es) 2008-10-24

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800804A CL2008000804A1 (es) 2007-03-23 2008-03-20 Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible.

Country Status (26)

Country Link
US (1) US20080233182A1 (OSRAM)
EP (1) EP2124973B1 (OSRAM)
JP (1) JP2010521534A (OSRAM)
KR (1) KR101688656B1 (OSRAM)
AR (1) AR065791A1 (OSRAM)
AU (1) AU2008231847B2 (OSRAM)
BR (1) BRPI0809258B8 (OSRAM)
CA (1) CA2681514C (OSRAM)
CL (1) CL2008000804A1 (OSRAM)
CO (1) CO6230993A2 (OSRAM)
DK (1) DK2124973T3 (OSRAM)
EC (1) ECSP099700A (OSRAM)
ES (1) ES2542694T3 (OSRAM)
GT (1) GT200900251A (OSRAM)
IL (1) IL201109A (OSRAM)
MA (1) MA31293B1 (OSRAM)
MX (1) MX2009010244A (OSRAM)
MY (1) MY164520A (OSRAM)
NZ (1) NZ579852A (OSRAM)
PE (1) PE20090186A1 (OSRAM)
PL (1) PL2124973T3 (OSRAM)
PT (1) PT2124973E (OSRAM)
RU (1) RU2009139002A (OSRAM)
TN (1) TN2009000387A1 (OSRAM)
TW (1) TW200904456A (OSRAM)
WO (1) WO2008116806A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102118478B1 (ko) 2009-03-09 2020-06-04 바스프 에이에스 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법
AR118962A1 (es) * 2019-05-22 2021-11-10 Bayer Consumer Care Ag Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (OSRAM) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
CN102908361A (zh) * 2004-07-09 2013-02-06 罗伯特·萨宾 治疗哺乳动物疾病的组合物及使用方法
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EA010802B1 (ru) * 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения

Also Published As

Publication number Publication date
ECSP099700A (es) 2009-11-30
US20080233182A1 (en) 2008-09-25
KR101688656B1 (ko) 2016-12-21
TN2009000387A1 (en) 2010-12-31
PT2124973E (pt) 2015-09-01
KR20100015799A (ko) 2010-02-12
ES2542694T3 (es) 2015-08-10
IL201109A (en) 2016-10-31
PL2124973T3 (pl) 2015-10-30
DK2124973T3 (da) 2015-06-22
CO6230993A2 (es) 2010-12-20
PE20090186A1 (es) 2009-03-20
GT200900251A (es) 2018-10-08
BRPI0809258A2 (pt) 2014-09-23
MA31293B1 (fr) 2010-04-01
JP2010521534A (ja) 2010-06-24
TW200904456A (en) 2009-02-01
IL201109A0 (en) 2010-05-17
EP2124973B1 (en) 2015-05-27
BRPI0809258B8 (pt) 2021-05-25
EP2124973A1 (en) 2009-12-02
WO2008116806A1 (en) 2008-10-02
MX2009010244A (es) 2009-10-26
CA2681514C (en) 2016-11-08
MY164520A (en) 2017-12-29
BRPI0809258B1 (pt) 2019-10-01
AU2008231847A1 (en) 2008-10-02
AU2008231847B2 (en) 2012-12-06
RU2009139002A (ru) 2011-04-27
NZ579852A (en) 2012-03-30
CA2681514A1 (en) 2008-10-02
AR065791A1 (es) 2009-07-01

Similar Documents

Publication Publication Date Title
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
CL2013002083A1 (es) Compuestos derivados de 2-amino-5-(trifluorometil)-furo[3,4-d]tiazina, como inhibidores de la produccion de la proteina beta-amiloide; composicion farmaceutica; y su uso para tratar o prevenir una enfermedad neurodegenerativa tal como demencia tipo alzheimer y demencia senil, y para tratar o prevenir la diabetes tipo 2.
AR066564A1 (es) Una combinacion farmaceutica sinergica para el tratamiento de cancer
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
MX2008005853A (es) Mezclas insecticidas sinergicas para el tratamiento de las semillas
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
IL190695A (en) Use of analogue compastatin to prepare a pharmaceutical composition for the treatment of macular degeneration
CL2013000850A1 (es) Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
LT3708178T (lt) Peptidas, skirtas naudoti makulos degeneracijos prevencijai arba gydymui
CL2007002669A1 (es) Compuestos derivados de benzoxazol-2,7-disustituido y oxazol[5,4-c]-piridina; proceso de fabricacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por las cinasas jack2 y/o jack3 tal como cancer.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BRPI1013763A2 (pt) Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
IL204658A (en) Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
CL2011002130A1 (es) Uso de una composicion que comprende una mezcla fisica o combinacion de polvos, granulos, cristales o agregados de sales de calcio, magnecio y hierro para el tratamiento de enfermedades relacionadas con la absorcion alterada de fosforo en seres humanos y animales.
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.